477585-26-5

Basic information

• Product Name: Benzenesulfonic acid, 4-[(2-methyl-4-quinolinyl)methoxy]-, sodium salt
• CAS NO: 477585-26-5
• Molecular Formula: C17H15NO4S.Na
• Molecular Weight: 351.358
• Mol File: 477585-26-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenesulfonic acid, 4-[(2-methyl-4-quinolinyl)methoxy]-, sodium salt(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonic acid, 4-[(2-methyl-4-quinolinyl)methoxy]-, sodium salt(477585-26-5)
• EPA Substance Registry System: Benzenesulfonic acid, 4-[(2-methyl-4-quinolinyl)methoxy]-, sodium salt(477585-26-5)

Safety Data

• Hazardous Substances Data: 477585-26-5(Hazardous Substances Data)

Upstream product

• 825-90-1 sodium p-hydroxybenzenesulfonate 
• 288399-19-9 4-(chloromethyl)-2-methylquinoline 
• 98-67-9 p-hydoroxybenzenesulfonic acid 

Downstream Products

• 1260171-34-3 methyl (S)-2-(4-benzylpiperazin-1-yl)-3-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonylamino]propanoate 
• 477585-31-2 4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl chloride hydrochloride salt 
• 607710-13-4 4-[(2-methyl-4-quinolyl)methoxy]benzenesulfonyl chloride 
• 1260171-71-8 methyl (S)-2-[4-(2-methylpropane-1-sulfonyl)piperazin-1-yl]-3-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonylamino]propanoate 
• 1260171-67-2 (S)-N-allyloxy-2-(4-isobutyrylpiperazin-1-yl)-3-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonylamino]propionamide 
• 1260171-61-6 (S)-N-hydroxy-2-(4-isobutyrylpiperazin-1-yl)-3-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonylamino]propionamide 

Relevant articles and documents

NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS

Provided herein are novel benzenesulfonamide compounds having a structure of formula (I) below: as well as to the method for synthesizing same and to the use thereof in pharmaceutical compositions to be used in human or veterinary medicine, as well as to

Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases

The present application describes novel uracil derivatives of formula I: A-W-U-X-Y-Z-Ua-Xa-Ya-Za??I or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, W, U, X, Y, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as inhibitors of TNF-α converting enzyme (TACE), matrix metalloproteinases (MMP), aggrecanase or a combination thereof.